Results 221 to 230 of about 151,660 (257)

Matrix metalloproteinase-1 therapy improves muscle healing

Journal of Applied Physiology, 2007
Muscle undergoes time-dependent phases of healing after injury, which ultimately results in residual fibrosis in the injured area. The use of exogenous matrix metalloproteinases (MMPs) may improve recovery after muscle injury by promoting the digestion of existing fibrous tissue and releasing local growth factors.
Hany, Bedair, T Thomas, Liu, Joel L, Kaar, Shawn, Badlani, Alan J, Russell, Yong, Li, Johnny, Huard   +6 more
openaire   +2 more sources

Matrix Metalloproteinase-1 and Cytokines in Patients with Acute Pancreatitis

Pancreas, 2003
Hypercytokinemia is known to occur in severe acute pancreatitis, suggesting that the production, deposition, and degradation of the extracellular matrix (ECM) occur actively as a result of the actions of the complicated cytokine network.To examine the influence of cytokines and growth factors on the ECM in acute pancreatitis from the points of view of ...
Hajime, Nakae, Shigeatsu, Endo, Yoshihiro, Inoue, Yasuhisa, Fujino, Go, Wakabayashi, Katsuya, Inada, Shigehiro, Sato   +6 more
openaire   +2 more sources

Inhibition of Matrix Metalloproteinase-1 by Dichloromethylene Bisphosphonate (Clodronate)

Calcified Tissue International, 1997
Interstitial collagenase present in human jaw cyst extract and purified human fibroblast-type collagenase (MMP-1) were both efficiently inhibited in vitro by clodronate, an osteoactive, antiresorptive bisphosphonate. The IC50 of clodronate to inhibit MMP-1 is 150 microM.
O, Teronen, Y T, Konttinen, C, Lindqvist, T, Salo, T, Ingman, A, Lauhio, Y, Ding, S, Santavirta, H, Valleala, T, Sorsa   +9 more
openaire   +2 more sources

Metal Ion Dependence of the Matrix Metalloproteinase-1 Mechanism

Biochemistry, 2015
Matrix metalloproteinase-1 (MMP-1) plays crucial roles in disease-related physiologies and pathological processes in the human body. We report here solution studies of MMP-1, including characterization of a series of mutants designed to bind metal in either the catalytic site or the structural site (but not both).
Hao, Yang, Katherine, Makaroff, Nicholas, Paz, Mahesh, Aitha, Michael W, Crowder, David L, Tierney   +5 more
openaire   +2 more sources

Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer

International Journal of Cancer, 1997
We analyzed blood plasma concentrations of matrix metalloproteinase-1 and -3 (MMP-1; MMP-3), the tissue inhibitor of metalloproteinase-1 (TIMP-1) and the complex MMP-1/TIMP-1, and looked for any correlation with prostate cancer stage. These components were measured by ELISA tests specific for these proteins in healthy male controls (n = 35), and in ...
K, Jung, L, Nowak, M, Lein, F, Priem, D, Schnorr, S A, Loening   +5 more
openaire   +2 more sources

Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer

The Journal of Pathology, 1998
The matrix metalloproteinases (MMPs) are a family of closely related proteolytic enzymes which are involved in the degradation of different components of the extracellular matrix. There is increasing evidence to indicate that individual MMPs have an important role in tumour invasion and tumour spread. Monoclonal antibodies specific for MMP-1, MMP-2, or
G I, Murray, M E, Duncan, P, O'Neil, J A, McKay, W T, Melvin, J E, Fothergill   +5 more
openaire   +2 more sources

Thyroid hormone induces myocardial matrix degradation by activating matrix metalloproteinase-1

Matrix Biology, 2007
Hyperthyroid patients develop left ventricular hypertrophy associated with alterations of several cardiac parameters such as heart rate, cardiac output, cardiac contraction and hemodynamic overload leading to cardiac complications. Although cardiac hypertrophy and contractile abnormality occur, interstitial fibrosis in the heart usually does not take ...
Sreerupa, Ghose Roy, Sumita, Mishra, Goutam, Ghosh, Arun, Bandyopadhyay   +3 more
openaire   +2 more sources

Effect of matrix metalloproteinase-1 promoter genotype on interleukin-1beta-induced matrix metalloproteinase-1 production in human periodontal ligament cells

Journal of Periodontal Research, 2010
Our previous studies have shown that a single nucleotide polymorphism at nucleotide -1607 of the human matrix metalloproteinase-1 (MMP-1) promoter is associated with the severity of periodontal disease. The purpose of this study was to evaluate the effect of different MMP-1 promoter genotypes on interleukin-1beta-induced MMP-1 production in human ...
Z, Cao, C, Li, J, Xiang
openaire   +2 more sources

Regulation of matrix metalloproteinase-1 and tissue inhibitor of matrix metalloproteinase-1 by dichloroacetic acid in human fibroblasts from normal peritoneum and adhesions

Fertility and Sterility, 2004
To examine the role of stimulation of aerobic metabolism on the differential expression of matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), which are differentially regulated in fibroblasts isolated from normal human peritoneum and adhesions.Tissue culture study.University research laboratory.Human ...
Michael P, Diamond, Eslam, El-Hammady, Rona, Wang, Ghassan, Saed   +3 more
openaire   +2 more sources

Evaluation of Matrix Metalloproteinase‐1 and Tissue Inhibitor of Metalloproteinase‐1 Levels in Gingival Fibroblasts of Cyclosporin A‐Treated Patients

Journal of Periodontology, 2002
Background: Cyclosporin A (CsA) is a potent immunosuppressant used to prevent organ transplant rejection and to treat various autoimmune diseases. CsA‐induced gingival overgrowth (CsA GO) is the most widely seen side effect of this drug; its pathogenesis is not completely understood.
Tuter, G, Serdar, MA, Yalim, M, Gurhan, IS, Balos, K   +4 more
openaire   +3 more sources